Moderna Completes Enrollment in Phase 2 COVID-19 Vaccine Study; Phase 3 Start on Track

Moderna (NASDAQ: MRNA) is one step closer to getting its COVID-19 vaccine, mRNA-1273, on the market. The biotech completed enrollment of 300 older adults, 55 years and older, in a phase 2 clinical trial. The other half of the clinical trial, 300 younger adults ages 18-55, was completed last month, but the older-adult cohort took longer to enroll because it was set up in two stages with a pause after 50 patients to observe safety.